

REMARKS

Claims 2-9, 14-17, 25, 29, 38, 44-61, 65-95, 97, 99 and 100-105 remain pending after this amendment.

The claims have been limited to the synthesis of novel polyamine compounds for use in experimental medicine. There is no claim to the efficacy of any drug in the treatment of any specific disease, in view of which the rejections under 35 U.S.C. 101 for lack of patentable utility, and under 35 U.S.C. 112 for failure to comply with enabling requirement are no longer applicable.


The synthesized compounds are novel. The disclosure provides extensive support for the premise that their specific compositions might be useful in treatment of the types of conditions listed in Claim 2. No such hypothesis can be found in the prior art. Consequently, there has been no incentive to synthesize the compounds for experimental use. In other words, the claimed syntheses are non-obvious.

Considering the lack of reference to specific diseases and the unitary character of the collection of compounds, the restriction of certain claims appear to be no longer warranted. All previously withdrawn claims have been reinstated and amended accordingly.

In view of the above, a favorable reexamination of the claims is earnestly solicited.

July 10, 2006

Respectfully submitted,



John D. Buchaca
Registration No. 37,289


1545 Hotel Circle South, Suite 150
San Diego, California 92108-3426
Telephone: (619) 294-2922
Fax No. (619) 294-8674

040316

AMENDMENT
Serial No. 10/017,235

040316

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 10, 2006, by John D. Buchaca, Reg. No. 37,289.

Signature:  Date: 10 July 2006